Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
A phase 3 trial of Daratumumab, Dexamethasone, Isatuximab in multiple myeloma, run by AstraZeneca, now recruiting.
Overview
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT is a phase 3 interventional study registered as NCT07764978 by AstraZeneca, with 750 participants planned, started 2026-06-26 and due to reach its primary completion in 2029-01-11. Interventions recorded: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide. Conditions listed: Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares AZD0120, Bortezomib, Daratumumab, Dexamethasone.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialIsatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Shares Isatuximab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialAZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Shares AZD0120, AstraZeneca, Multiple myeloma.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.